ImmunityBio/$IBRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ImmunityBio
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
- Ticker
- $IBRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 688
- Headquarters
- San Diego, United States
- Website
- immunitybio.com
ImmunityBio Metrics
BasicAdvanced
$9.3B
-
-$0.99
0.13
-
Price and volume
Market cap
$9.3B
Beta
0.13
52-week high
$12.43
52-week low
$1.95
Average daily volume
15M
Financial strength
Current ratio
5.721
Quick ratio
5.355
Long term debt to equity
-1.167
Total debt to equity
-1.175
Interest coverage (TTM)
-2.20%
Profitability
EBITDA (TTM)
-235.298
Gross margin (TTM)
99.34%
Net profit margin (TTM)
-598.56%
Operating margin (TTM)
-151.88%
Effective tax rate (TTM)
0.02%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-30.54%
Return on equity (TTM)
122.86%
Valuation
Price to revenue (TTM)
53.338
Price to book
-8.87
Price to tangible book (TTM)
-8.77
Price to free cash flow (TTM)
-30.65
Free cash flow yield (TTM)
-3.26%
Free cash flow per share (TTM)
-0.287
Growth
Revenue change (TTM)
192.92%
Earnings per share change (TTM)
104.25%
3-year revenue growth (CAGR)
554.26%
3-year earnings per share growth (CAGR)
-4.55%
What the Analysts think about ImmunityBio
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
Analyst projections of the future price of ImmunityBio stock.
Bulls say / Bears say
ANKTIVA sales are still ramping: second-quarter 2026 product revenue rose 92% year on year to $50.7 million and 15% sequentially, extending the run of sequential growth to eight quarters. That gives the company a growing commercial base to build on. (ImmunityBio)
The FDA expanded ANKTIVA’s bladder-cancer label to include papillary-only disease, making it the first approved treatment for that subgroup and widening access across BCG-unresponsive NMIBC. The broader label creates room to grow beyond the original CIS population. (Fierce Pharma, ImmunityBio)
A 366-patient randomised trial is testing ANKTIVA plus BCG in earlier-stage, BCG-naïve bladder cancer, with results expected in November 2026. The company says an FDA-requested interim analysis found longer complete-response duration with the combination, though the final results are still pending. (ImmunityBio)
The business remains cash-hungry: operating cash outflow was $141.9 million in the first half of 2026, and the company says it may need further financing. That creates a risk of more borrowing or share issuance before product sales cover its costs. (StockTitan)
ANKTIVA faces established competition, and its use depends on BCG supply; Johnson & Johnson’s Inlexzo does not require BCG and has reported strong response data. Rivals could limit ANKTIVA’s uptake, particularly where BCG is difficult to obtain. (The Closing Print)
The shares trade on a demanding valuation relative to current sales: one recent analysis put the price-to-sales ratio at about 60, versus 9.5 for peers. That leaves little room for weaker sales growth or disappointing clinical progress before expectations are reset. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
ImmunityBio Financial Performance
Revenues and expenses
ImmunityBio Earnings Performance
Company profitability
Upcoming events
No upcoming events
ImmunityBio News
AllArticlesVideos
ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment
Benzinga2 weeks ago
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
Business Wire2 weeks ago
ImmunityBio Stock Climbs Thursday: What's Going On?
Benzinga2 weeks ago
Funds containing ImmunityBio
Fund name | Fund size | $IBRX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.60% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.60% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.30% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.30% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.30% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.